Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• EPS beat: Compass Therapeutics reported Q earnings of ($0.09) per share, beating the consensus estimate of ($0.10) by $0.01.
• Stock reaction and valuation: Shares traded up about 2.5% to $5.83 on the news; the company has a market cap of $1.04 billion, a negative PE, and its 50-/200-day moving averages are $5.88 and $4.77 respectively.
• Analyst and institutional sentiment: MarketBeat shows a consensus rating of "Moderate Buy" with a $13.36 price target, a majority of Buy ratings, and roughly 68.4% of the shares held by institutions amid recent position changes.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01, FiscalAI reports.

Compass Therapeutics Stock Up 2.5%

CMPX traded up $0.14 during trading on Thursday, hitting $5.83. The company had a trading volume of 453,195 shares, compared to its average volume of 2,287,071. The company has a market capitalization of $1.04 billion, a PE ratio of -12.96 and a beta of 1.48. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The firm's 50-day moving average price is $5.88 and its 200 day moving average price is $4.77.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Xponance LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $55,000. CIBC Bancorp USA Inc. acquired a new position in Compass Therapeutics during the third quarter worth $37,000. Creative Planning bought a new position in Compass Therapeutics in the second quarter valued at $30,000. Finally, Victory Capital Management Inc. increased its stake in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after buying an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an "outperform" rating for the company. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research note on Wednesday, February 4th. Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They set a "buy" rating and a $15.00 target price for the company. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.36.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.